Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms
- 1 August 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (15) , 4738-4746
- https://doi.org/10.1158/1078-0432.ccr-06-0596
Abstract
Purpose: In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells. Experimental Design: Using a panel of four primary human glioblastoma cell lines with heterogeneous O6-methylguanine-DNA methyltransferase (MGMT) protein expression, normal human astrocytes, and U87 xenografts, we investigated (a) the relationship of MGMT status with efficacy of temozolomide-based chemoradiation using a panel of in vitro and in vivo assays; (b) underlying mechanisms by which temozolomide enhances radiation effect in glioblastoma cells; and (c) strategies to overcome resistance to radiation + temozolomide. Results: Temozolomide enhances radiation response most effectively in glioblastomas without detectable MGMT expression. On concurrent radiation + temozolomide administration in MGMT-negative glioblastomas, there seems to be decreased double-strand DNA (dsDNA) repair capacity and enhanced dsDNA damage compared either with radiation alone or with sequentially administered temozolomide. Our data suggest that O6-benzylguanine can enhance the antitumor effects of concurrent radiation + temozolomide in MGMT-positive cells by enhancing apoptosis and the degree of dsDNA damage. O6-Benzylguanine was most effective when administered concurrently with radiation + temozolomide and had less of an effect when administered with temozolomide in the absence of radiation or when administered sequentially with radiation. Our in vivo data using U87 xenografts confirmed our in vitro findings. Conclusions: The present study shows that temozolomide enhances radiation response most effectively in MGMT-negative glioblastomas by increasing the degree of radiation-induced double-strand DNA damage. In MGMT-positive glioblastomas, depletion of MGMT by the addition of O6-benzylguanine significantly enhances the antitumor effect of concurrent radiation + temozolomide. These are among the first data showing mechanisms of synergy between radiation and temozolomide and the effect of MGMT.Keywords
This publication has 21 references indexed in Scilit:
- O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cellsJournal of Neurochemistry, 2006
- Novel Radiation-Enhancing Agents in Malignant GliomasSeminars in Radiation Oncology, 2006
- Tails of histones in DNA double-strand break repairMutagenesis, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- High Doses of SN1 Type Methylating Agents Activate DNA Damage Signaling Cascades that are Largely Independent of Mismatch RepairCell Cycle, 2005
- Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma PatientsClinical Cancer Research, 2004
- Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient CellsClinical Cancer Research, 2004
- O 6-Benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomasNeuro-Oncology, 2004
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBritish Journal of Cancer, 2003
- Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after SurgeryNew England Journal of Medicine, 1980